Literature DB >> 20619383

Preventive and therapeutic potential of placental extract in contact hypersensitivity.

Youn Son Kim1, Jang-June Park, Yukimi Sakoda, Yuming Zhao, Katsuya Hisamichi, Tai-Ichi Kaku, Koji Tamada.   

Abstract

Immunoregulatory effects of placental extract and placenta-derived factors have been demonstrated in various conditions. Accordingly, placental extract has been used as certain types of medical intervention in Asian countries, whereas experimental evidence supporting its therapeutic effects and mechanisms has yet to be fully demonstrated. In this study, we investigate preventive and therapeutic effects of placental extract in contact hypersensitivity (CHS), a mouse model of allergic contact dermatitis. Administration of placental extract prior to the sensitization of allergic antigen (Ag) significantly inhibited the severity of CHS induced by Ag challenge. This effect was associated with reduced numbers of CD4(+) T cells in peripheral blood, decrease of tissue-infiltrating lymphocytes, and preferential production of Th2-type cytokines in Ag-challenged sites. In addition, CHS caused by repetitive challenges of allergic Ag was also prevented and treated by administration of placental extract. Finally, administration of cyclo-trans-4-L-hydroxyprolyl-L-serine, a dipeptide derived from placental extract, also alleviated CHS, suggesting its potential role in the effects of placental extract in CHS. Taken together, our findings demonstrated experimental evidence supporting immunoregulatory effects of placental extract in allergic skin diseases and elucidated its potential mechanisms.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20619383      PMCID: PMC2949509          DOI: 10.1016/j.intimp.2010.06.024

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  50 in total

1.  Stimulation of thymidine incorporation in keratinocytes by insulin, epidermal growth factor, and placental extract: comparison with cell number to assess growth.

Authors:  E J O'Keefe; M L Chiu
Journal:  J Invest Dermatol       Date:  1988-01       Impact factor: 8.551

2.  Changes in epidermal growth factor receptor and its messenger ribonucleic acid levels in human placenta and isolated trophoblast cells during pregnancy.

Authors:  C F Chen; H Kurachi; Y Fujita; N Terakawa; A Miyake; O Tanizawa
Journal:  J Clin Endocrinol Metab       Date:  1988-12       Impact factor: 5.958

3.  Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses.

Authors:  Fumihiko Tsushima; Hideyuki Iwai; Noriko Otsuki; Masaaki Abe; Sachiko Hirose; Tomohide Yamazaki; Hisaya Akiba; Hideo Yagita; Yuzo Takahashi; Ken Omura; Ko Okumura; Miyuki Azuma
Journal:  Eur J Immunol       Date:  2003-10       Impact factor: 5.532

4.  Hepatocyte growth factor in human placenta and trophoblastic disease.

Authors:  H K Wolf; R Zarnegar; L Oliver; G K Michalopoulos
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

5.  Regulation of inhibin secretion in human placental cell culture by epidermal growth factor, transforming growth factors, and activin.

Authors:  J Qu; K Thomas
Journal:  J Clin Endocrinol Metab       Date:  1993-10       Impact factor: 5.958

6.  Regulation of contact hypersensitivity by interleukin 10.

Authors:  T A Ferguson; P Dube; T S Griffith
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

7.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1.

Authors:  Mehrdad Matloubian; Charles G Lo; Guy Cinamon; Matthew J Lesneski; Ying Xu; Volker Brinkmann; Maria L Allende; Richard L Proia; Jason G Cyster
Journal:  Nature       Date:  2004-01-22       Impact factor: 49.962

8.  Immunohistochemical localization of epidermal growth factor in human endometrium, decidua, and placenta.

Authors:  G E Hofmann; R T Scott; P A Bergh; L Deligdisch
Journal:  J Clin Endocrinol Metab       Date:  1991-10       Impact factor: 5.958

9.  Subtypes of betaglycan and of type I and type II transforming growth factor-beta (TGF-beta) receptors with different affinities for TGF-beta 1 and TGF-beta 2 are exhibited by human placental trophoblast cells.

Authors:  E J Mitchell; L Fitz-Gibbon; M D O'Connor-McCourt
Journal:  J Cell Physiol       Date:  1992-02       Impact factor: 6.384

10.  A potential transforming growth factor alpha/epidermal growth factor receptor autocrine circuit in placental cytotrophoblasts.

Authors:  M S Filla; C X Zhang; K L Kaul
Journal:  Cell Growth Differ       Date:  1993-05
View more
  5 in total

1.  In vitro evaluation of the effects of human umbilical cord extracts on human fibroblasts, keratinocytes, and melanocytes.

Authors:  Phuc Van Pham; Loan Thi-Tung Dang; Uyen Thanh Dinh; Huyen Thi-Thu Truong; Ba Ngoc Huynh; Dong Van Le; Ngoc Kim Phan
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-10-26       Impact factor: 2.416

2.  Human placental extract activates a wide array of gene expressions related to skin functions.

Authors:  Phooi-Yee Chang; Lit-Chein Chin; Koichi Kimura; Yasukazu Nakahata
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

3.  Canine Placenta Recellularized Using Yolk Sac Cells with Vascular Endothelial Growth Factor.

Authors:  Paula Fratini; Nathia Nathaly Rigoglio; Gustavo de Sá Schiavo Matias; Ana Claudia O Carreira; Rose Eli Grassi Rici; Maria Angelica Miglino
Journal:  Biores Open Access       Date:  2018-07-01

4.  Placental extract suppresses cardiac hypertrophy and fibrosis in an angiotensin II-induced cachexia model in mice.

Authors:  Akihiro Yamauchi; Akiko Kamiyoshi; Takayuki Sakurai; Hiroyuki Miyazaki; Eiichi Hirano; Hong Seok Lim; Taiichi Kaku; Takayuki Shindo
Journal:  Heliyon       Date:  2019-10-13

Review 5.  Antiviral properties of placental growth factors: A novel therapeutic approach for COVID-19 treatment.

Authors:  Meghnad G Joshi; Jeevitaa Kshersagar; Shashikant R Desai; Shimpa Sharma
Journal:  Placenta       Date:  2020-08-06       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.